The DOI matches its Crossref record.
Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis
Abstract
Very little is known about the natural history, effects of therapy, and survival after recurrence of hepatocellular carcinoma (HCC) after liver transplantation. All adult patients undergoing liver transplant from September 19, 1988, until September 19, 2002, were reviewed. Only patients with histologically proven HCC in the explant who subsequently developed recurrence were included in further analysis. The endpoints analyzed were survival from time of transplant and survival from time of recurrence. Recipient demographics and laboratory values, technique of transplant (whole cadaver, split, or living donor), and tumor characteristics were analyzed. The time to, location of, and any medical or surgical treatment of recurrences also were considered. Of the 311 patients with HCC in the explant, 57 (18.3%) eventually were diagnosed with recurrent tumor after transplant. Median time to recurrence was 12.3. Five-year survival was significantly lower for patients with recurrence (22%) than for patients without recurrence (64%)(P < 0.0001). Multivariate analysis demonstrated that the size and differentiation of the original tumor, as well as the presence of bone recurrence, were independently associated with survival from transplant in patients with recurrence. When survival from the time of recurrence was analyzed, multivariate analysis showed that the absence of bone metastases, recurrence more than 12 months from transplant, and surgical treatment of the recurrence were independently associated with significantly longer survival. In conclusion, recurrence of HCC significantly shortens survival after transplant. Nonetheless, some patients with recurrence can be expected to live for a considerable period of time. Recurrent disease should be treated surgically when possible, because surgery is independently associated with longer survival. (Liver Transpl 2004;10:534-540.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mazzaferro, V., Bhoori, S., Sposito, C., Bongini, M., Langer, M., Miceli, R., & Mariani, L. (2011) · Liver Transplantation · doi:10.1002/lt.22365 · Cited by 593
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches
Sapisochin, G., & Bruix, J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.193 · Cited by 436
Recurrence after liver resection for hepatocellular carcinoma: Risk factors, treatment, and outcomes
Shah, S. A., Cleary, S. P., Wei, A. C., Yang, I., Taylor, B. R., Hemming, A. W., Langer, B., Grant, D. R., Greig, P. D., & Gallinger, S. (2007) · Surgery · doi:10.1016/j.surg.2006.06.028 · Cited by 420
Korean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
Heterogeneity of liver cancer and personalized therapy
Li, L., & Wang, H. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.07.018 · Cited by 339
Toso, C., Asthana, S., Bigam, D. L., Shapiro, A. M. J., & Kneteman, N. M. (2009) · Hepatology · doi:10.1002/hep.22693 · Cited by 332
Zimmerman, M. A. (2008) · Archives of Surgery · doi:10.1001/archsurg.2007.39 · Cited by 278
Practice guidelines for management of hepatocellular carcinoma 2009
Korean Liver Cancer Study Group and National Cancer Center, K. (2009) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2009.15.3.391 · Cited by 257
Bone metastases from hepatocellular carcinoma: clinical features and prognostic factors
Lu, Y., Hu, J.-G., Lin, X.-J., & Li, X.-G. (2017) · Hepatobiliary & Pancreatic Diseases International · doi:10.1016/s1499-3872(16)60173-x · Cited by 26
Metadata
- Authors
- Roayaie, S., Schwartz, J. D., Sung, M. W., Emre, S. H., Miller, C. M., Gondolesi, G. E., Krieger, N. R., & Schwartz, M. E.
- Venue
- Liver Transplantation
- Published
- 2004-04
- Volume
- 10
- Issue
- 4
- Pages
- 534-540
- ISSN
- 1527-6465 (ISSN-L)
- OpenAlex
- W1976082980
- Cited by
- 455
- References
- 0
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.